{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T09:49:41Z","timestamp":1648547381050},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annales de Cardiologie et d'Ang\u00e9iologie"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.ancard.2012.01.004","type":"journal-article","created":{"date-parts":[[2012,2,16]],"date-time":"2012-02-16T06:11:02Z","timestamp":1329372662000},"page":"245-251","source":"Crossref","is-referenced-by-count":0,"title":["Facteurs de risque de complications digestives des patients sous antiagr\u00e9gant plaquettaire suivis en cardiologie de ville\u00a0: description et prise en charge"],"prefix":"10.1016","volume":"61","author":[{"given":"G.","family":"Ducrocq","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.-A.","family":"Bigard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Marouene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.-H.","family":"Delaage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Fabry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Barthelemy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.-G.","family":"Steg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ancard.2012.01.004_bib0005","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/bmj.308.6923.235","article-title":"Collaborative overview of randomised trials of antiplatelet therapy--III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients","volume":"308","author":"Antiplatelet Trialists\u2019 Collaboration","year":"1994","journal-title":"BMJ"},{"key":"10.1016\/j.ancard.2012.01.004_bib0010","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1136\/bmj.321.7270.1183","article-title":"Risk of gastrointestinal haemorrhage with long-term use of aspirin: meta-analysis","volume":"321","author":"Derry","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.ancard.2012.01.004_bib0015","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1093\/eurheartj\/ehp256","article-title":"Gastrointestinal bleeding in high-risk survivors of myocardial infarction: the VALIANT Trial","volume":"30","author":"Moukarbel","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ancard.2012.01.004_bib0020","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1136\/gut.2005.080754","article-title":"Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations","volume":"55","author":"Lanas","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.ancard.2012.01.004_bib0025","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/S0140-6736(07)60722-3","article-title":"Summing the risk of NSAID therapy","volume":"369","author":"Scheiman","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ancard.2012.01.004_bib0030","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/clpt.1993.115","article-title":"Adverse effects of low-dose aspirin in a healthy elderly population","volume":"54","author":"Silagy","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ancard.2012.01.004_bib0035","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1046\/j.1365-2036.2003.01693.x","article-title":"High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease","volume":"18","author":"Ng","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ancard.2012.01.004_bib0040","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa020496","article-title":"Warfarin, aspirin, or both after myocardial infarction","volume":"347","author":"Hurlen","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ancard.2012.01.004_bib0045","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1111\/j.1572-0241.2000.02248.x","article-title":"Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin","volume":"95","author":"Sorensen","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ancard.2012.01.004_bib0050","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study","volume":"284","author":"Silverstein","year":"2000","journal-title":"Jama"},{"key":"10.1016\/j.ancard.2012.01.004_bib0055","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/ar146","article-title":"The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents","volume":"3","author":"Garcia Rodriguez","year":"2001","journal-title":"Arthritis Res"},{"key":"10.1016\/j.ancard.2012.01.004_bib0060","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1365-2036.2006.02829.x","article-title":"The prevalence of risk factors for gastrointestinal complications and use of gastroprotection among persons hospitalized for cardiovascular disease","volume":"23","author":"Targownik","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ancard.2012.01.004_bib0065","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2006.02759.x","article-title":"Upper gastrointestinal bleeding associated with antiplatelet drugs","volume":"23","author":"Ibanez","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ancard.2012.01.004_bib0070","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1572-0241.2006.01062.x","article-title":"Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants","volume":"102","author":"Lanas","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ancard.2012.01.004_bib0075","unstructured":"Cayla G, Collet JP, Silvain J, Thiefin G, Woimant F, Montalescot G. Prevalence and clinical impact of upper gastrointestinal symptoms in subjects treated with low dose aspirin: the UGLA survey. Int J Cardiol 2010 [Epub ahead of print]."},{"key":"10.1016\/j.ancard.2012.01.004_bib0080","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.amjcard.2005.01.049","article-title":"Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials","volume":"95","author":"Serebruany","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ancard.2012.01.004_bib0085","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.amjmed.2005.10.039","article-title":"Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials","volume":"119","author":"McQuaid","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.ancard.2012.01.004_bib0090","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ahj.2008.07.026","article-title":"Design and rationale of CURRENT-OASIS 7: a randomized, 2\u00d72 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy","volume":"156","author":"Mehta","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.ancard.2012.01.004_bib0095","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(96)01254-8","article-title":"Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product","volume":"348","author":"Kelly","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.ancard.2012.01.004_bib0100","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","author":"CAPRIE Steering Committee","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.ancard.2012.01.004_bib0105","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa042087","article-title":"Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding","volume":"352","author":"Chan","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ancard.2012.01.004_bib0110","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1056\/NEJMoa012877","article-title":"Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use","volume":"346","author":"Lai","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ancard.2012.01.004_bib0115","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.jacc.2008.08.002","article-title":"ACCF\/ACG\/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents","volume":"52","author":"Bhatt","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ancard.2012.01.004_bib0120","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jacc.2007.06.064","article-title":"Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study","volume":"51","author":"Gilard","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ancard.2012.01.004_bib0125","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jama.2009.261","article-title":"Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome","volume":"301","author":"Ho","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.ancard.2012.01.004_bib0130","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0140-6736(09)61525-7","article-title":"Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials","volume":"374","author":"O\u2019Donoghue","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ancard.2012.01.004_bib0160","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1161\/CIRCULATIONAHA.110.965640","article-title":"Clinical events as a function of PPI use, clopidogrel use and CYP2C19 genotype in a large nationwide cohort of acute myocardial infarction: Results from the FAST-MI Registry","volume":"123","author":"Simon","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ancard.2012.01.004_bib0140","unstructured":"Goodman SGCR, Pieper KS, James SK, Nicolau JC, Storey RF, Cantor WJ, et al., Proton pump inhibitor use is likely a marker for, rather than a cause of, a higher risk of cardiovascular events: insights from PLATO. Circulation (in press)."},{"key":"10.1016\/j.ancard.2012.01.004_bib0145","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ancard.2012.01.004_bib0150","doi-asserted-by":"crossref","unstructured":"Wurtz M, Grove EL, Kristensen SD, Hvas AM. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart 96:368\u201371.","DOI":"10.1136\/hrt.2009.181107"},{"key":"10.1016\/j.ancard.2012.01.004_bib0155","doi-asserted-by":"crossref","first-page":"378","DOI":"10.7326\/0003-4819-153-6-201009210-00005","article-title":"Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study","volume":"153","author":"Charlot","year":"2010","journal-title":"Ann Intern Med"}],"container-title":["Annales de Cardiologie et d'Ang\u00e9iologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003392812000054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003392812000054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T04:29:05Z","timestamp":1543206545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003392812000054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0003392812000054"],"URL":"https:\/\/doi.org\/10.1016\/j.ancard.2012.01.004","relation":{},"ISSN":["0003-3928"],"issn-type":[{"value":"0003-3928","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}